

# Special Feature\_2

## An Outstanding Oncology Strategy

### Focused on Millennium's global oncology strategy, Takeda Group aims to become a leader in the oncology field

2008 was a remarkable year of progress for Takeda's oncology strategy through the inclusion of Millennium within the Takeda Group. In Millennium's first year as a Takeda organization and as leader of Takeda's global oncology strategy, Takeda Group's clinical oncology programs were successfully transferred to Millennium, and new medicines from the various discovery sites in Tsukuba, Osaka, San Francisco and San Diego were able to advance into the clinic. This close partnership with Takeda's global network has allowed for a smooth transition for Millennium to become The Takeda Oncology Company. The combined oncology pipeline of Takeda and Millennium could bring significant advances in treating patients with cancer. While many challenges remain in an increasingly competitive environment, Takeda Group is well poised for success.



(From left): Zhi Li, Ben Knight, Millennium Pharmaceuticals, Inc.

**Overview of Millennium's Business Performance in 2008**

In June, 2008 the FDA approved *VELCADE* (generic name: bortezomib) in combination for the treatment of patients with previously untreated multiple myeloma, a rare blood cancer. Previously, this first-in-class cancer therapy had been approved for patients who had failed one prior therapy as well as for patients with relapsed mantle cell lymphoma (a form of non-Hodgkin's Lymphoma (NHL)).

The FDA approval opened up an opportunity for a new group of patients, who could potentially benefit from *VELCADE* based therapy. In addition, the scientific rigor and potential implications for patients based on the pivotal Phase III clinical trial data led to its subsequent publication in the *New England Journal of Medicine (NEJM)* in August, 2008.

After this approval, *VELCADE* total revenues increased 41 percent in fiscal 2008 with total revenues of \$409 million\*, up from \$290 million in the same period of the previous year. Available in 88 countries, more than 100,000 people have used *VELCADE* worldwide. Additionally, now as part of the Takeda Group, Millennium, along with its co-development



Deborah Dunsire, M.D.  
President and CEO  
Millennium: The Takeda Oncology Company

partner Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is continuing to explore the benefits of *VELCADE* in patients with non-Hodgkin's lymphoma (follicular and indolent types) as well as other types of cancer.

\* *VELCADE* sales for May-March FY2008 (following consolidation with Takeda Group) were \$375 million.




*VELCADE*, a novel treatment for multiple myeloma and non-Hodgkin's lymphoma




Millennium research laboratory

**VELCADE—US FY Net Sales**



With highly skilled and driven employees, Millennium and Takeda remain committed to outstanding science and attracting, growing and retaining top talent. In fact, since joining the Takeda Group, Millennium continues to be an employer of choice, and in 2008, *Science Magazine*, *The Scientist* and *The Boston Globe* recognized Millennium as a top employer based on its ability to cultivate exemplary life science professionals.



Model of a VELCADE molecule

## Maximizing synergies between our global research centers, Takeda has a bold vision, "WE ASPIRE TO CURE CANCER"

### Takeda's Strategy in Oncology

Cancer is forecast to be the leading cause of death as early as 2010. Our vision is clear—We Aspire To Cure Cancer. We will get there by delivering extraordinary medicines for people with cancer worldwide through our science, innovation and passion. This is a bold vision and ambitious mission, but one that guides our research, development and commercial organizations to achieve our leadership goals.

To attain global leadership, we have charted a path that will:

- Continue delivering *VELCADE* to patients in its current indications and expanding its development in new indications.
- Leverage our expertise in protein homeostasis—the science behind *VELCADE*—to bring forward improved products in this class. The first such product entered the clinic in fiscal 2008 and could be even more efficacious with broader utility than *VELCADE*, including both oral and intravenous formulations.
- Build upon the solid foundation established by Takeda with leuporelin acetate for patients with prostate cancer by bringing forward innovative treatment options like TAK-700 (17, 20 lyase inhibitor)

and TAK-683/TAK-448 (metastin inhibitors).


- Improve the probability of success and our competitive position with development programs by focusing on translational medicine from discovery throughout the product life cycle.

- Leverage strategic business relationships, like our ongoing collaboration with Harvard Medical School in protein homeostasis, which bolsters our access to novel science that may lead to innovative medicines.

- Expand and balance the portfolio via selective mergers, acquisitions and in-licensing opportunities. In June, 2009 Takeda acquired IDM Pharma, a company whose main asset is *MEPACT* (generic name: mifamurtide), a drug for malignant bone cancer that recently was approved in Europe.

Ultimately, increasing awareness, boosting enrollment in our clinical trials and fully understanding the advanced molecules in our pipeline translates into hope and promise for patients everywhere. We are committed to meeting the needs of people with cancer by bringing important new medicines to them as quickly, effectively and safely as possible.

### Global Research Centers



### Promising Pipeline Compounds

Building a leading drug pipeline requires a focus on high quality and sufficient quantity, disciplined portfolio management and a collaborative culture. After integrating the Takeda oncology clinical programs, our pipeline consists of 18 potential cancer medicines\* and is among the largest in the industry. We have four oncology programs in Phase III, including *VELCADE* for follicular NHL and first line mantle cell lymphomas, AMG 706 (motesanib) co-developed with Amgen for non-small cell lung cancer, and Vectibix (panitumumab) for colon or rectal cancer, currently under regulatory review (Japan only).

\* As of the announcement of fiscal 2009 1st quarter financial results (as of the end of July 2009).

Additional clinical development programs continue to progress. Data highlighting these developments have been presented at renowned worldwide scientific conferences, such as the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and the American Society of Hematology (ASH).

Our scientists are focusing on discovering first-in-class or best-in-class molecules, which we believe is



advancing the treatment of cancer. Millennium is recognized as the scientific leader in protein homeostasis, a research area with roots in Nobel-Prize winning science. Data recently published in *Nature* about MLN4924 is just one example of ways in which the homeostatic balance of cellular proteins is being explored to address many disease states. Examples of potential best-in-class programs include MLN9708, a second generation proteasome inhibitor with oral and intravenous formulations being explored in solid tumors and hematologic malignancies and TAK-700, an oral small molecule being studied in prostate cancer.

### Significantly Enhanced Oncology Pipeline

Phase I		Phase II	Phase III	Filed
TAK-700 Prostate cancer	TAK-701* Advanced malignancies	CBP501* Malignant pleural mesothelioma, Non small cell lung cancer	<i>VELCADE</i> Follicular NHL, MCL	Vectibix* Progressive and relapse cancer of the colon and rectum
TAK-683 Prostate cancer	MLN9708 Advanced malignancies	MLN0518 Glioblastoma	AMG 706* Progressive non small cell lung cancer	
TAK-448 Prostate cancer	MLN4924 Advanced malignancies	MLN8237 Acute myelogenous leukemia and others	Vectibix* Head and neck cancer	
TAK-285 Solid tumors	AMG 706* Breast cancer			
TAK-593 Solid tumors	AMG 655* Progressive cancer			
TAK-901 Advanced malignancies	AMG 386* Progressive cancer			
	AMG 479* Progressive cancer			

Takeda  
 Millennium  
 Amgen  
 \* Licensed products